Evidence map›Paper›PMID 30214146›Full record

ArticleClinical ophthalmology (Auckland, N.Z.)2018

Effect of quantitative intraocular pressure reduction on visual field defect progression in normal tension glaucoma under medical therapy applying Markov model.

Keiji Yoshikawa, Kazunori Santo, Hiroko Hizaki, Masayo Hashimoto

Open access · goldAbstract read
In one paragraph

Article in Clinical ophthalmology (Auckland, N.Z.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Keiji YoshikawaYoshikawa Eye Clinic, Machida, Tokyo, Japan, keiyomd@ark.ocn.ne.jp.
Kazunori SantoJapan Medical Affairs, Santen Pharmaceutical Co., Ltd, Osaka, Japan.
Hiroko HizakiJapan Medical Affairs, Santen Pharmaceutical Co., Ltd, Osaka, Japan.
Masayo HashimotoJapan Medical Affairs, Santen Pharmaceutical Co., Ltd, Osaka, Japan.
Santen (Japan) · JPMinamiaoyama Eye Clinic · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo quantitatively evaluate the association of intraocular pressure (IOP) reduction with visual field defect (VFD) progression in normal tension glaucoma (NTG) under medical therapy. PATIENTS AND

methodsClinical data for 622 eyes of 311 primary open-angle glaucoma and NTG patients were collected from April 2006 to March 2016. Of these patients, those with normal IOP, glaucomatous VFD by Anderson's criteria, corrected visual acuity ≥0.7, >5 years of medical therapy, ≥5 visual field tests at least five times at 12-month intervals, visual field testing reliability coefficients of ≤33%, and mean deviation (MD) exceeding below -20 dB in the initial visual field test were included in this retrospective data analysis. MD and IOP data were collected at baseline and after 5 years. Following MD categorization into stages I to IV, stage transition matrices were generated using a Markov model to evaluate VFD changes. Eyes were divided based on IOP reduction (0%, 10%, 15%, 20%, 25%, 30%) from baseline. VFD aggravations were compared using the Markov model and MD slopes with IOP reduction rates as cutoff values.

resultsOverall, 132 eyes of 132 NTG patients fulfilled the eligibility criteria. MD decreased significantly (

conclusionIn NTG patients, VFD aggravation was significantly suppressed in groups with IOP reductions of ≥25% from baseline.

Indexed as

intraocular pressure reductionlong-term follow-upMarkov modelnormal tension glaucomavisual field defect (VFD) progression

Identifiers

PMID30214146
PMCPMC6124460
OpenAlexW2889482376

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.